A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms ReTHINK
- Sponsors Novartis Pharmaceuticals Corporation
- 19 Jul 2017 This trial was completed in Austria, according to European Clinical Trials Database record.
- 07 Jul 2017 This trial was completed in Belgium, according to European Clinical Trials Database record.
- 26 May 2017 Planned primary completion date changed from 24 Mar 2021 to 15 Oct 2017.